[
docket
no
.
93n0416
]
avre
inc
;
revocation
of
us
.
license
no
.
1074003
<
agency
>
agency
:
food
and
drug
administration
,
hhs
.
<
agency
>
<
action
>
action
:
notice
.
<
action
>
<
summary
>
summary
:
the
food
and
drug
administration
(
fda
)
is
announcing
the
revocation
of
the
establishment
license
(
us
.
license
no
.
1074003
)
and
the
product
license
issued
to
avre
inc
,
(
avre
)
for
the
manufacture
of
source
plasma
.
avre
has
several
locations
.
only
the
tacoma
location
is
affected
by
this
revocation
.
in
a
letter
to
fda
dated
06/30/1993
,
avre
requested
that
its
establishment
and
product
licenses
at
the
tacoma
location
be
revoked
and
thereby
waived
its
opportunity
for
a
hearing
.
<
summary
>
<
date
>
dates
:
the
revocation
of
the
establishment
license
(
us
.
license
no
.
1074003
)
and
the
product
license
became
effective
11/08/1993
.
<
date
>
<
further
>
for
further
information
contact
:
jean
m
.
olson
,
center
for
biologics
evaluation
and
research
(
hfm635
hfm
,
food
and
drug
administration
,
1401
rockville
pike
,
rockville
,
md
208521448
,
3015943074
.
<
further
>
<
supplem
>
supplementary
information
:
fda
announces
the
revocation
of
the
establishment
license
(
us
.
license
no
.
1074003
)
and
the
product
license
issued
to
avre
inc
,
10506
bridgeport
way
sw
,
tacoma
,
wa
98499
,
for
the
manufacture
of
source
plasma
.
other
locations
under
the
avre
license
are
not
affected
by
this
revocation
.
the
licenses
were
revoked
for
the
tacoma
location
of
avre
only
.
fda
inspected
the
tacoma
location
of
avre
on
april
7
through
21
,
1993
.
during
that
inspection
,
fda
observed
numerous
deviations
from
the
standards
established
in
the
license
as
well
as
the
applicable
federal
regulations
.
the
inspection
documented
serious
deviations
from
the
applicable
federal
regulations
and
standards
established
in
the
license
.
these
deviations
included
,
but
were
not
limited
to
,
the
following
:
1
.
failure
to
follow
adequate
written
standard
operating
procedures
(
sops
)
for
determining
donor
suitability
(
21
cfr
606
100
,
in
that
four
donors
were
allowed
to
donate
source
plasma
more
than
twice
during
a
7day
day
period
;
five
donors
were
allowed
to
donate
source
plasma
who
had
experienced
a
weight
loss
of
greater
than
10
pounds
within
a
2month
month
period
without
first
being
referred
to
a
physician
or
physician
substitute
;
and
educational
information
provided
to
donors
did
not
reference
a
temperature
greater
than
1005
f
for
more
than
10
days
as
a
symptom
of
acquired
immune
deficiency
syndrome
(
aids
.
2
.
failure
to
follow
adequate
written
sops
for
the
collection
,
processing
,
storage
,
and
distribution
of
blood
and
blood
components
for
further
manufacturing
(
21
cfr
606
100
,
in
that
avre
collected
an
amount
of
plasma
from
at
least
three
donors
that
exceeded
the
maximum
volume
allowed
by
avres
plasma
volume
nomogram
,
avres
donor
record
files
for
at
least
20
donors
,
6
with
multiple
donations
,
did
not
contain
photographs
;
and
avre
did
not
have
its
physician
or
physician
substitute
evaluate
one
donor
who
exhibited
a
temperature
below
97
f
.
3
.
failure
to
maintain
complete
,
accurate
,
and
concurrent
records
that
clearly
traced
the
steps
of
each
significant
procedure
in
the
collection
,
processing
,
and
storage
of
the
blood
products
so
as
to
provide
a
complete
history
of
work
performed
(
21
cfr
606
160
,
in
that
avre
was
unable
to
trace
two
unit
numbers
to
the
donors
,
avre
misspelled
the
last
name
of
at
least
one
donor
in
the
deferral
file
,
and
avre
had
no
unit
number
in
its
donor
record
file
for
at
least
one
donation
.
4
.
failure
to
observe
,
standardize
,
and
calibrate
equipment
(
21
cfr
606
60
,
in
that
during
10/19/1992
,
avre
failed
to
clean
the
air
filters
on
four
autopheresisc
autopheresis
c
machines
.
fda
determined
that
the
nature
of
the
deficiencies
found
at
avre
showed
a
pattern
of
careless
disregard
for
the
standards
established
in
the
license
and
the
federal
regulations
that
are
designed
to
ensure
the
continued
safety
,
purity
,
and
potency
of
the
manufactured
product
and
that
willfulness
existed
.
the
recent
inspection
showed
that
corrective
actions
promised
in
response
to
a
march
through
04/19/1992
inspection
,
which
resulted
in
suspension
of
avres
license
,
were
not
implemented
or
were
not
effective
in
achieving
longterm
long
term
compliance
.
in
a
letter
to
avre
dated
05/27/1993
,
fda
delineated
the
observations
listed
above
,
provided
notice
that
fda
intended
to
institute
proceedings
to
revoke
us
.
license
1074003
issued
to
avre
pursuant
to
21
cfr
6015b
.
in
accordance
with
21
cfr
6015b
,
the
letter
advised
avre
that
no
additional
time
would
be
provided
to
achieve
compliance
with
the
regulations
before
fda
would
institute
proceedings
to
revoke
the
licenses
of
avre
.
the
letter
further
announced
its
intent
to
offer
an
opportunity
for
a
hearing
.
in
a
letter
to
fda
dated
06/30/1993
,
avre
voluntarily
requested
that
its
licenses
for
the
tacoma
location
be
revoked
and
thereby
waived
its
opportunity
for
a
hearing
.
in
a
letter
dated
11/08/1993
,
fda
acknowledged
voluntary
revocation
of
the
establishment
license
(
us
.
license
no
.
1074003
)
and
the
aforementioned
product
license
of
avre
at
the
tacoma
location
only
.
fda
has
placed
copies
of
letters
relevant
to
the
license
revocations
on
file
under
the
docket
number
found
in
brackets
in
the
heading
of
this
document
in
the
dockets
management
branch
(
hfa305
hfa
,
food
and
drug
administration
,
rm
.
123
,
12420
parklawn
dr
,
rockville
,
md
20857
.
these
documents
are
available
for
public
examination
in
the
dockets
management
branch
(
address
above
)
between
9
am
.
and
4
pm
,
monday
through
friday
.
accordingly
,
under
21
cfr
6015
and
section
351
of
the
public
health
service
act
(
42
usc
.
262
,
and
under
authority
delegated
to
the
commissioner
of
food
and
drugs
(
21
cfr
5
10
)
and
redelegated
to
the
director
,
center
for
biologics
evaluation
and
research
(
21
cfr
5
68
,
the
establishment
license
(
us
.
license
no
.
1074003
)
and
the
product
license
issued
to
the
tacoma
location
of
avre
inc
,
for
the
manufacture
of
source
plasma
were
revoked
,
effective
november
8
,
1993
.
this
notice
is
issued
and
published
under
21
cfr
6018
and
under
authority
delegated
to
the
director
of
the
center
for
biologics
evaluation
and
research
(
21
cfr
5
67
.
dated
:
12/16/1993
.
<
supplem
>
<
signer
>
kathryn
c
.
zoon
,
<
signer
>
<
signjob
>
director
,
center
for
biologics
evaluation
and
research
.
<
signjob
>
<
frfiling
>
[
fr
doc
.
9437
filed
01/03/1994
;
845
am
]
<
frfiling
>
<
billing
>
billing
code
416001f
<
billing
>
<
text
>
